Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Immunization against full-length protein and peptides from the Lutzomyia longipalpis sand fly salivary component maxadilan protects against Leishmania major infection in a murine model.

Wheat WH, Arthun EN, Spencer JS, Regan DP, Titus RG, Dow SW.

Vaccine. 2017 Dec 4;35(48 Pt B):6611-6619. doi: 10.1016/j.vaccine.2017.10.039. Epub 2017 Oct 24.

2.

2,3,7,8-tetrachlorodibenzo-p-dioxin slows the progression of experimental cutaneous Leishmaniasis in susceptible BALB/c and SCID mice.

DeKrey GK, Teagarden RE, Lenberg JL, Titus RG.

PLoS One. 2013 Oct 1;8(10):e76259. doi: 10.1371/journal.pone.0076259. eCollection 2013.

3.

BluePort: a platform to study the eosinophilic response of mice to the bite of a vector of Leishmania parasites, Lutzomyia longipalpis sand flies.

Mejia JS, Toot-Zimmer AL, Schultheiss PC, Beaty BJ, Titus RG.

PLoS One. 2010 Oct 27;5(10):e13546. doi: 10.1371/journal.pone.0013546.

4.

State-dependent life history models in a changing (and regulated) environment: steelhead in the California Central Valley.

Satterthwaite WH, Beakes MP, Collins EM, Swank DR, Merz JE, Titus RG, Sogard SM, Mangel M.

Evol Appl. 2010 May;3(3):221-43. doi: 10.1111/j.1752-4571.2009.00103.x. Epub 2009 Nov 20.

5.

Cysteine-free proteins in the immunobiology of arthropod-borne diseases.

Mejia JS, Arthun EN, Titus RG.

J Biomed Biotechnol. 2010;2010:171537. doi: 10.1155/2010/171537. Epub 2010 Jan 4.

6.

Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis.

Modolell M, Choi BS, Ryan RO, Hancock M, Titus RG, Abebe T, Hailu A, Müller I, Rogers ME, Bangham CR, Munder M, Kropf P.

PLoS Negl Trop Dis. 2009 Jul 14;3(7):e480. doi: 10.1371/journal.pntd.0000480.

8.

Protection of susceptible BALB/c mice from challenge with Leishmania major by nucleoside hydrolase, a soluble exo-antigen of Leishmania.

Al-Wabel MA, Tonui WK, Cui L, Martin SK, Titus RG.

Am J Trop Med Hyg. 2007 Dec;77(6):1060-5.

PMID:
18165522
9.

Objective evaluation of skin prick test reactions using digital photography.

dos Santos RV, Titus RG, Lima HC.

Skin Res Technol. 2007 May;13(2):148-53.

PMID:
17374055
11.

Immunomodulatory effects of the Lutzomyia longipalpis salivary gland protein maxadilan on mouse macrophages.

Brodie TM, Smith MC, Morris RV, Titus RG.

Infect Immun. 2007 May;75(5):2359-65. Epub 2007 Mar 5.

12.

Effect of Lutzomyia longipalpis salivary gland extracts on leukocyte migration induced by Leishmania major.

Monteiro MC, Lima HC, Souza AA, Titus RG, Romão PR, Cunha FQ.

Am J Trop Med Hyg. 2007 Jan;76(1):88-94.

PMID:
17255235
13.

2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) reduces Leishmania major burdens in C57BL/6 mice.

Bowers OJ, Sommersted KB, Sowell RT, Boling GE, Hanneman WH, Titus RG, Dekrey GK.

Am J Trop Med Hyg. 2006 Oct;75(4):749-52.

PMID:
17038706
14.

Salivary gland extracts of Culicoides sonorensis inhibit murine lymphocyte proliferation and no production by macrophages.

Bishop JV, Mejia JS, Pérez de León AA, Tabachnick WJ, Titus RG.

Am J Trop Med Hyg. 2006 Sep;75(3):532-6.

15.

Is it possible to develop pan-arthropod vaccines?

Mejia JS, Bishop JV, Titus RG.

Trends Parasitol. 2006 Aug;22(8):367-70. Epub 2006 Jun 19. Review.

PMID:
16784890
16.
17.

Novel compounds active against Leishmania major.

St George S, Bishop JV, Titus RG, Selitrennikoff CP.

Antimicrob Agents Chemother. 2006 Feb;50(2):474-9.

19.

The surface-mosaic model in host-parasite relationships.

Mejia JS, Moreno F, Muskus C, Vélez ID, Titus RG.

Trends Parasitol. 2004 Nov;20(11):508-11. Review.

PMID:
15471701
20.

Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major.

Tonui WK, Mejia JS, Hochberg L, Mbow ML, Ryan JR, Chan AS, Martin SK, Titus RG.

Infect Immun. 2004 Oct;72(10):5654-61.

22.
23.

Lutzomyia longipalpis salivary gland homogenate impairs cytokine production and costimulatory molecule expression on human monocytes and dendritic cells.

Costa DJ, Favali C, Clarêncio J, Afonso L, Conceição V, Miranda JC, Titus RG, Valenzuela J, Barral-Netto M, Barral A, Brodskyn CI.

Infect Immun. 2004 Mar;72(3):1298-305.

24.
26.

Infection with Leishmania major stimulates haematopoiesis in susceptible BALB/c mice and suppresses haematopoiesis in resistant CBA mice.

Guilpin VO, Nosbisch L, Titus RG, Swardson-Olver CJ.

Parasitology. 2003 Mar;126(Pt 3):187-94.

PMID:
12666877
27.

Maxadilan, the vasodilator/immunomodulator from Lutzomyia longipalpis sand fly saliva, stimulates haematopoiesis in mice.

Guilpin VO, Swardson-Olver C, Nosbisch L, Titus RG.

Parasite Immunol. 2002 Aug;24(8):437-46.

28.

Type 1 and type 2 responses to Leishmania major.

Rogers KA, DeKrey GK, Mbow ML, Gillespie RD, Brodskyn CI, Titus RG.

FEMS Microbiol Lett. 2002 Mar 19;209(1):1-7. Review.

29.

Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection.

Morris RV, Shoemaker CB, David JR, Lanzaro GC, Titus RG.

J Immunol. 2001 Nov 1;167(9):5226-30.

30.
32.

Regulation of differentiation to the infective stage of the protozoan parasite Leishmania major by tetrahydrobiopterin.

Cunningham ML, Titus RG, Turco SJ, Beverley SM.

Science. 2001 Apr 13;292(5515):285-7.

33.

Identification of an IL-2 binding protein in the saliva of the Lyme disease vector tick, Ixodes scapularis.

Gillespie RD, Dolan MC, Piesman J, Titus RG.

J Immunol. 2001 Apr 1;166(7):4319-26.

35.

Rapid early onset lymphocyte cell death in mice resistant, but not susceptible to Leishmania major infection.

Desbarats J, Stone JE, Lin L, Zakeri ZF, Davis GS, Pfeiffer LM, Titus RG, Newell MK.

Apoptosis. 2000 Apr;5(2):189-96.

PMID:
11232247
36.
37.

The immunomodulatory factors of bloodfeeding arthropod saliva.

Gillespie RD, Mbow ML, Titus RG.

Parasite Immunol. 2000 Jul;22(7):319-31. Review.

38.

Priming of a beta-galactosidase (beta-GAL)-specific type 1 response in BALB/c mice infected with beta-GAL-transfected Leishmania major.

Chakkalath HR, Siddiqui AA, Shankar AH, Dobson DE, Beverley SM, Titus RG.

Infect Immun. 2000 Feb;68(2):809-14.

39.
40.

A method for the isolation and analysis of leucocytic cells from Leishmanial ear lesions in mice.

DeKrey GK, Titus RG.

J Immunol Methods. 1999 Aug 31;228(1-2):1-11.

PMID:
10556537
41.
42.

Variation in the salivary peptide, maxadilan, from species in the Lutzomyia longipalpis complex.

Lanzaro GC, Lopes AH, Ribeiro JM, Shoemaker CB, Warburg A, Soares M, Titus RG.

Insect Mol Biol. 1999 May;8(2):267-75.

PMID:
10380110
43.

Indomethacin treatment slows disease progression and enhances a Th1 response in susceptible BALB/c mice infected with Leishmania major.

De Freitas LA, Mbow LM, Estay M, Bleyenberg JA, Titus RG.

Parasite Immunol. 1999 May;21(5):273-7.

45.
46.

The PACAP-type I receptor agonist maxadilan from sand fly saliva protects mice against lethal endotoxemia by a mechanism partially dependent on IL-10.

Bozza M, Soares MB, Bozza PT, Satoskar AR, Diacovo TG, Brombacher F, Titus RG, Shoemaker CB, David JR.

Eur J Immunol. 1998 Oct;28(10):3120-7.

50.

Analysis of the immune responses of mice to infection with Leishmania braziliensis.

DeKrey GK, Lima HC, Titus RG.

Infect Immun. 1998 Feb;66(2):827-9.

Supplemental Content

Loading ...
Support Center